Hi-C FFPE Sequencing for Detection of Fusions andRearrangements that are Diagnostic, Prognostic, andTherapeutic Biomarkers in Lymphoma
Xu-Monette, et al.
AMP Europe 2026 - Tallinn, Estonia
Hi-C Sequencing Outperforms High-Coverage WGSfor Detection of Diagnostic Fusions and Rearrangementsin FFPE Lymphoma Specimens
Sikkink, et al.
AMP Europe 2026 - Tallinn, Estonia
Hi-C sequencing to identify clinically actionable fusions in non–small cell lung cancer missed by other sequencing technologies
Levine, et al.
ASCO 2026 - Chicago, IL
Discovery and functional characterization of enhancer hijacking oncogene rearrangements in NSCLC using Hi-C sequencing of FFPE tumors
Sikkink, et al.
AACR 2026 - San Diego, CA
Detection and functional assessment of extrachromosomal DNA amplifications in FFPE lung tumor specimens using Hi-C sequencing
Sikkink, et al.
AACR 2026 - San Diego, CA
Genome wide testing of archived ovarian and uterine carcinosarcoma FFPE tissue using FusionPlus Hi-C to determine HRD status
Bradshaw, et al.
AACR 2026 - San Diego, CA
Targetable fusions and rearrangement detection in gastrointestinal and lungtumors leveraging low-pass whole-genome sequencing based Hi-C chemistry
Sigal, et al.
AACR 2026 - San Diego, CA
Actionable fusions and rearrangements can be efficiently identified by Hi-C whole genome sequencing in lung tumors
Hastie, et al.
AACR 2026 - San Diego, CA
Clinical use of genome-wide Hi-C sequencing for assessment of structural variants in diffuse large B-cell lymphoma.
Michaels, et al.
ASH 2025 - Orlando, FL
Hi-C FFPE sequencing analysis is highly concordant with FISH and detects additional variants informing diagnosis and treatment in diffuse large B-cell lymphoma
Xu-Monette, et al.
ASH 2025 - Orlando, FL
Application of Hi-c sequencing to detect cryptic and novel structural aberrations in lymphoid neoplasms
Rozenova, et al.
ASH 2025 - Orlando, FL
Cytogenetic Advances in NHL Diagnosis by Leveraging Hi-C Sequencing
Sikkink, et al.
AMP 2025 - Boston, MA
Hi-C FFPE Sequencing for Detection of Fusions and Rearrangements that are Diagnostic, Prognostic, and Therapeutic Biomarkers in Lymphoma
Hastie, et al.
Lymphoma, Leukemia & Myeloma Congress 2025 - NY, NY
Molecular Analysis of Driver Negative Lung Cancer for Rearrangements and Fusions Using a New HiC Sequencing Assay
Ricketts, et al.
2025 World Conference on Lung Cancer - Barcelona, Spain
Aventa Lymphoma based on Hi-C FFPE Sequencing is an Alternative to FISH and Detects Additional Variants Informing Diagnosis and Therapy in Lymphomas
Hastie, et al.
16th Annual Meeting of the Cancer Genomics Consortium - Houston, TX
Aventa FusionPlus based on Hi-C FFPE Sequencing Detects Fusions Genome-Wide with High Sensitivity in Solid Tumors
Hastie, et al.
16th Annual Meeting of the Cancer Genomics Consortium - Houston, TX